Brokers Set Expectations for ResMed's Q1 Earnings (NYSE:RMD)

ResMed Inc. (NYSE:RMD - Free Report) - William Blair cut their Q1 2026 EPS estimates for ResMed in a research note issued to investors on Thursday, April 24th. William Blair analyst M. Andrew now expects that the medical equipment provider will post earnings of $2.45 per share for the quarter, down from their previous forecast of $2.66. The consensus estimate for ResMed's current full-year earnings is $9.47 per share. William Blair also issued estimates for ResMed's Q2 2026 earnings at $2.57 EPS.

Several other research analysts have also recently issued reports on the stock. Royal Bank of Canada increased their price objective on shares of ResMed from $247.00 to $255.00 and gave the company a "sector perform" rating in a report on Thursday. Citigroup upgraded shares of ResMed from a "neutral" rating to a "buy" rating in a report on Wednesday, March 5th. Piper Sandler decreased their price objective on shares of ResMed from $260.00 to $248.00 and set a "neutral" rating for the company in a report on Thursday. KeyCorp set a $274.00 price objective on shares of ResMed in a report on Thursday. Finally, Morgan Stanley began coverage on shares of ResMed in a report on Wednesday, March 19th. They set an "overweight" rating and a $280.00 target price for the company. One research analyst has rated the stock with a sell rating, six have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $258.83.

ResMed Stock Performance

Shares of NYSE:RMD traded down $1.82 during trading hours on Friday, hitting $234.06. The stock had a trading volume of 1,117,896 shares, compared to its average volume of 1,017,721. The stock's fifty day simple moving average is $221.92 and its 200 day simple moving average is $234.00. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.29 and a current ratio of 3.33. The firm has a market capitalization of $34.38 billion, a price-to-earnings ratio of 27.63, a PEG ratio of 1.53 and a beta of 0.75. ResMed has a 1-year low of $179.42 and a 1-year high of $263.05.

ResMed (NYSE:RMD - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $2.37 EPS for the quarter, beating the consensus estimate of $2.36 by $0.01. ResMed had a net margin of 25.34% and a return on equity of 26.17%. The company had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.28 billion. During the same quarter last year, the business earned $2.13 earnings per share. ResMed's revenue was up 7.9% compared to the same quarter last year.

ResMed Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 12th. Investors of record on Thursday, May 8th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 0.91%. The ex-dividend date is Thursday, May 8th. ResMed's dividend payout ratio is 23.79%.

Insiders Place Their Bets

In other ResMed news, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $219.74, for a total value of $439,480.00. Following the completion of the sale, the director now owns 73,218 shares in the company, valued at $16,088,923.32. This represents a 2.66 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael J. Farrell sold 8,009 shares of the firm's stock in a transaction on Monday, April 7th. The shares were sold at an average price of $209.85, for a total transaction of $1,680,688.65. Following the transaction, the chief executive officer now owns 455,472 shares in the company, valued at $95,580,799.20. This represents a 1.73 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 49,013 shares of company stock worth $11,298,816 in the last quarter. 0.71% of the stock is currently owned by corporate insiders.

Institutional Trading of ResMed

A number of institutional investors and hedge funds have recently modified their holdings of RMD. GAMMA Investing LLC lifted its position in shares of ResMed by 23,982.6% during the 1st quarter. GAMMA Investing LLC now owns 733,556 shares of the medical equipment provider's stock worth $164,207,000 after purchasing an additional 730,510 shares during the last quarter. Invesco Ltd. raised its holdings in shares of ResMed by 32.2% in the 4th quarter. Invesco Ltd. now owns 2,325,009 shares of the medical equipment provider's stock worth $531,706,000 after buying an additional 566,046 shares in the last quarter. Norges Bank acquired a new position in shares of ResMed in the 4th quarter worth approximately $118,605,000. Captrust Financial Advisors raised its holdings in shares of ResMed by 813.4% in the 4th quarter. Captrust Financial Advisors now owns 443,340 shares of the medical equipment provider's stock worth $101,387,000 after buying an additional 394,803 shares in the last quarter. Finally, AQR Capital Management LLC raised its holdings in shares of ResMed by 133.6% in the 4th quarter. AQR Capital Management LLC now owns 625,054 shares of the medical equipment provider's stock worth $142,944,000 after buying an additional 357,466 shares in the last quarter. 54.98% of the stock is currently owned by institutional investors and hedge funds.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.